Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Deferred Taxes: 2016-2024

Historic Deferred Taxes for Ptc Therapeutics (PTCT) over the last 8 years, with Dec 2024 value amounting to -$55.9 million.

  • Ptc Therapeutics' Deferred Taxes rose 300.00% to $2,000 in Q1 2025 from the same period last year, while for Mar 2025 it was -$55.9 million, marking a year-over-year decrease of 19.14%. This contributed to the annual value of -$55.9 million for FY2024, which is 19.14% down from last year.
  • Per Ptc Therapeutics' latest filing, its Deferred Taxes stood at -$55.9 million for FY2024, which was down 19.14% from -$46.9 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Deferred Taxes ranged from a high of $5.9 million in FY2020 and a low of -$55.9 million during FY2024.
  • Its 3-year average for Deferred Taxes is -$45.7 million, with a median of -$46.9 million in 2023.
  • Data for Ptc Therapeutics' Deferred Taxes shows a maximum YoY plummeted of 9,191.78% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Ptc Therapeutics' Deferred Taxes stood at $5.9 million in 2020, then tumbled by 93.58% to $377,000 in 2021, then crashed by 9,191.78% to -$34.3 million in 2022, then slumped by 36.92% to -$46.9 million in 2023, then dropped by 19.14% to -$55.9 million in 2024.